Patients with type 2 diabetes could have their risk of kidney complications or death from heart disease greatly reduced by a combination of blood sugar control and two blood-pressure lowering drugs.
Intensive blood sugar control based on gliclazide modified release (Diamicron MR), together with intensive blood pressure lowering based on a fixed combination of perindopril and indapamide (Preterax), has been found to reduce the risk of death from heart disease by 24% and kidney complications by 33% in such patients.
The results from ADVANCE (Action in Diabetes and Vascular Disease), the largest ever trial performed in patients with type 2 diabetes, were presented at the European Association for the Study of Diabetes (EASD) congress.
They provide further evidence for a new therapeutic strategy with the potential to save lives and protect millions of diabetics worldwide from serious complications.
The results also represent an important step forward for the management of millions of people with diabetes worldwide, as the treatment strategy reduced both the likelihood of developing and dying from the complications of diabetes.
The researchers, from Australia’s George Institute for International Health, conclude that an intensive and progressive glucose control strategy can play an important role in treating patients with type 2 diabetes, in particular in protecting the kidneys.
Copyright PA Business 2008